
-
Immuneering Corporation NasdaqGM:IMRX Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 that is in Phase 1/2a clinical trial for the treatment of patients with solid tumors. Immuneering Corporation was incorporated in 2008 and is based in Cambridge, Massachusetts.
Location: 245 Main Street, Cambridge, MA, 02142, United States | Website: https://immuneering.com | Industry: Biotechnology | Sector: Healthcare
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
20.04M
Cash
35.87M
Avg Qtr Burn
-13.4M
Short % of Float
3.17%
Insider Ownership
24.00%
Institutional Own.
12.58%
Qtr Updated
03/31/25
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
IMM-1-104 Details Solid tumor/s, Cancer, Pancreatic cancer | Phase 2a Data readout | |
IMM-1-104 + G12C inhibitor Details Cancer, Non-small cell lung carcinoma | Phase 2a Initiation | |
IMM-1-104 + BRAF inhibitor Details Cancer, Melanoma | Phase 2a Initiation | |
IMM-1-104 + PD-1 inhibitor Details Cancer, Melanoma | Phase 2a Initiation | |
IMM-1-104 + Libtayo Details Cancer, Non-small cell lung carcinoma | Phase 2a Initiation | |
IMM-6-415 Details Solid tumor/s | Phase 1/2 Data readout |